Routine Clinical Practice
OtherThis is an observational study
NCT Number: NCT03394521
The purpose of this study is to measure how many patients develop worsening glaucoma in the early years (2-4 years) of routine monitoring in hospital eye services. We will study a group of patients who were initially diagnosed as having glaucoma, or having high pressure in the eye (ocular hypertension) or having been diagnosed as a glaucoma suspect.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
In the UK, patients with possible signs of glaucoma or ocular hypertension (OHT) are usually picked up at a routine sight test at their optician or general practitioner. These patients are usually diagnosed in secondary care hospital eye services by an ophthalmologist.
In addition to those diagnosed with OHT and glaucoma there are a large group of patients who have ocular characteristics similar to those found in glaucoma patients, but could also represent variations in normality. In this group, 'glaucoma suspects', monitoring in secondary care for a number of years is recommended in order to establish whether they have glaucoma or if after several years of monitoring there are no clear signs of glaucoma the patient may be discharged.
In our study we will conduct a case-note review of a well-defined cohort of patients who were first identified through a diagnostic accuracy study (the GATE study). This includes (1) patients with OHT, (2) patients identified as glaucoma suspects and (3) patients diagnosed with glaucoma. We will investigate how many patients have experience worsening disease and how many patients have been discharged due to a low risk of glaucoma. We will also investigate the relationship between baseline demographic characteristics and characteristics of the eye and progression of disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Eligibility for patients to be recruited into the GATE study was as follows:
Inclusion criteria
Exclusion criteria
This study cohort is further defined from the GATE population as
Selection criteria:
This is an observational study
Time frame: 4 years
Proportion of glaucoma suspects and OHT patients who develop glaucoma annually up to 4 years after diagnosis in secondary care
Time frame: 1,2,3,4 years
Proportion of the cohort of glaucoma patients with progression of disease up to 4 years
Time frame: 4 years
Evaluation of predictors of disease progression from baseline demographic and ocular characteristics
University of Aberdeen
Other
Progression Evaluation in Glaucoma (PEG): Progression of Disease in Patients Newly Diagnosed With Glaucoma and Glaucoma Suspects Participating in the GATE Study
Acronym: PEG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07550712
Eye Diseases, Glaucoma
Taipei, Taiwan
View Trial DetailsNCT07318428
Age Related Macular Degeneration, Cardiovascular Diseases
Busan, South Korea
View Trial DetailsNCT02710916
Eye Diseases, Glaucoma
Bordeaux, Aquitaine, France
View Trial DetailsNCT06689696
Eye Diseases, GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Fullerton, California, United States
View Trial Details